ScreenerHero

RNAZ TransCode Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · transcodetherapeutics.com
1.760USD-1.12%Mkt Cap: 29.80M $P/E: —

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap29.80M USD
Enterprise Value188.46M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.66M USD
Revenue/Share—
Last Price1.760 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.97
PEG—
EV/EBITDA-7.46
EV/Revenue—
P/S—
P/B-0.07
EPS (TTM)-52.65
EPS (Forward)-0.60
52W Range
1.5201% of range20.99
52W High20.99 USD
52W Low1.520 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.82%
ROA-21.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.52M USD
CapEx (TTM)6.66K USD
FCF Margin—
FCF Yield-46.24%
Net Debt-7.73M USD
Net Debt/EBITDA0.31
Balance Sheet
Debt/Equity0.00
Current Ratio1.97
Quick Ratio1.55
Book Value/Sh-27.38 USD
Cash/Share0.49 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:28
Split DateMay 15, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.16.93M
Float2.15M
Insiders1.78%
Institutions0.44%
Short Interest
Short Ratio0.7d
Short % Float0.36%
Short % Out.0.36%
Shares Short61.40K
Short (prev mo.)30.91K
Technical
SMA 502.709 (-35.0%)
SMA 2006.708 (-73.8%)
Beta1.26
S&P 52W Chg16.45%
Avg Vol (30d)49.53K
Avg Vol (10d)67.47K
Technical Indicators
RSI (14)35.3
MACD-0.4055
MACD Signal-0.5438
MACD Hist.+0.1382
BB Upper1.942 USD
BB Middle1.712 USD
BB Lower1.481 USD
BB Width26.93%
ATR (14)0.2569 USD
Vol Ratio (20d)0.61x